Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [18 F]FDG-PET: comparison with cardiac MRI and monitoring erythropoietin therapy by Stefan Brunner et al.
Brunner et al. EJNMMI Research 2012, 2:43
http://www.ejnmmires.com/content/2/1/43ORIGINAL RESEARCH Open AccessLeft ventricular functional assessment in murine
models of ischemic and dilated cardiomyopathy
using [18 F]FDG-PET: comparison with cardiac MRI
and monitoring erythropoietin therapy
Stefan Brunner1†, Andrei Todica2†, Guido Böning2, Stefan G Nekolla3, Moritz Wildgruber4, Sebastian Lehner2,
Martina Sauter5, Christopher Übleis2, Karin Klingel5, Paul Cumming6, Wolfgang Michael Franz1 and Marcus Hacker2*Abstract
Background: We performed an initial evaluation of non-invasive ECG-gated [18 F]FDG-positron emission
tomography (FDG-PET) for serial measurements of left ventricular volumes and function in murine models of dilated
(DCM) and ischemic cardiomyopathy (ICM), and then tested the effect of erythropoietin (EPO) treatment on DCM
mice in a preliminary FDG-PET therapy monitoring study.
Methods: Mice developed DCM 8 weeks after injection with Coxsackievirus B3 (CVB3), whereas ICM was induced
by ligation of the left anterior descending artery. LV volumes (EDV and ESV) and the ejection fraction (LVEF) of
DCM, ICM and healthy control mice were measured by FDG-PET and compared with reference standard results
obtained with 1.5 T magnetic resonance imaging (MRI). In the subsequent monitoring study, LVEF of DCM mice
was evaluated by FDG-PET at baseline, and after 4 weeks of treatment, with EPO or saline.
Results: LV volumes and the LVEF as measured by FDG-PET correlated significantly with the MRI results. These
correlations were higher in healthy and DCM mice than in ICM mice, in which LVEF measurements were somewhat
compromised by absence of FDG uptake in the area of infarction. LV volumes (EDV and ESV) were systematically
underestimated by FDG-PET, with net bias such that LVEF measurements in both models of heart disease exceeded
by 15% to 20% results obtained by MRI. In our subsequent monitoring study of DCM mice, we found a significant
decrease of LVEF in the EPO group, but not in the saline-treated mice. Moreover, LVEF in the EPO and saline mice
significantly correlated with histological scores of fibrosis.
Conclusions: LVEF estimated by ECG-gated FDG-PET significantly correlated with the reference standard MRI, most
notably in healthy mice and mice with DCM. FDG-PET served for longitudinal monitoring of effects of EPO
treatment in DCM mice.
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Murine models of cardiovascular disease are increas-
ingly important for evaluation of novel therapeutic
approaches. A primary endpoint in such models is left
ventricular ejection fraction (LVEF), which is a strong
independent predictor of cardiovascular morbidity and
death [1,2]. Several techniques have been developed
for the assessment of left ventricle (LV) function in
small animal investigations. Pressure-volume relations
can be measured with a conductance microcatheter,
with the caveat that this invasive method is not per-
missive to follow-up examinations in small animals [3].
Echocardiography is widely used in mice, despite its
high intra- and inter-observer variability [4]. In the
clinical setting, cardiac magnetic resonance imaging
(MRI) and blood pool single-photon emission com-
puted tomography are considered as gold standards for
the assessment of LVEF [5-7], but have not found wide
use for monitoring cardiac therapies in mice.
As an alternative to these approaches, positron emis-
sion tomography (PET) with the glucose analogue
[18 F]-fluorodeoxyglucose (FDG), allows analysis of car-
diac function and myocardial metabolism within the
same setting [8,9]. Indeed, FDG-PET has been evaluated
against reference standard MRI methods for the calcu-
lation of LV function in healthy mice and in mice with
ischemic cardiomyopathy (ICM) due to myocardial
infarction (MI) [10-12], but has not yet been tested
in murine models of dilative cardiomyopathy (DCM).
Furthermore, the fitness of the applicability of gated
FDG-PET for therapeutic monitoring in mouse models
of myocardial diseases has not been established.
Therefore, we compared the accuracy of ECG-gated
FDG-PET LVEF measurements in healthy mice, and
in murine models of ICM and also in DCM-induced
by Coxsackievirus B3 (CVB3) exposure. Quantitative
results were compared with reference standard LV-
function measurements obtained with 1.5 T clinical MRI.
We then proceeded to test gated FDG-PET for longitu-
dinal monitoring in mice with CVB3-induced DCM after
erythropoietin (EPO) treatment, based upon previous
reports of its cardioprotective properties in preclinical
models of myocardial infarction [13,14] as well as in rats
with autoimmune-induced myocarditis [15,16].
Methods
Animal models
To obtain a murine model of ICM, MI was induced in
(N= 7) male C57BL/6 wildtype (WT) mice (Charles
River Laboratories, Sulzbach, Germany) by surgical oc-
clusion of the left anterior descending artery (LAD), as
described previously [17]. Mice were examined by PET
and MRI 4 weeks after MI. To obtain a murine model of
DCM, SWR/J (H-2q) mice (N= 11) were infected withCVB3 via intraperitoneal injection (1 × 105 pfu [5]) [18].
This procedure provokes mice to develop acute myocar-
ditis at 6 to 12 days after injection, and subsequently to
proceed to a chronic phase of myocarditis, resulting sev-
eral weeks later in a DCM phenotype [19]. Our DCM
mice were examined by PET and MRI 12 weeks after in-
fection, with healthy, age-matched SWR/J (H-2q)-mice
(N= 4) serving as controls. For all imaging examinations,
anaesthesia was induced with isoflurane (2.5%) and
maintained throughout the examination with isoflurane
(1.5%) delivered in oxygen (1.2 L/min) via a mask. Animal
care and all experimental procedures were performed in
strict accordance to the Guide for the Care and Use of
Laboratory Animals published by the US National Insti-
tutes of Health (NIH publication no. 85–23, revised 1996)
and was approved by the local animal care and use
committees.
Administration of EPO
In a separate intervention/treatment study, SWR/J (H-2q)
mice (N=11) with CVB3-induced DCM underwent a
baseline FDG-PET examination 8 weeks after CVB3 in-
fection. Following this scan, mice were randomised into
groups which were treated thrice weekly for 2 weeks with
subcutaneous injections of saline (N=5) or EPO
(2000 IU/kg; erythropoietin alpha, Janssen-Cilag, Neuss,
Germany; N= 6). Follow-up scans were performed 2 weeks
after completion of the treatment, thus 4 weeks after the
baseline scans.
Cardiac magnetic resonance imaging
For reliable ECG synchronisation and high resolution
imaging, a dedicated small animal ECG device, 1025-MR
(SA Instruments Inc., Stony Brook, NY), with a micros-
copy coil (Philips Medical Systems, Best, NL) was used.
Imaging was performed on a 1.5 T Philips Achieva MR
scanner using a clinical gradient system (30 mT/m, 150
mT/m/ms). The mice were imaged in prone position
with the thorax placed on top of the microscopy single
loop surface coil (D= 2.3 mm). High-resolution MRI
sequences for assessment of myocardial function and
morphology were implemented as described previously
[9]. In brief, cine MRI was performed with prospective
ECG gating using a spoiled gradient echo technique.
Imaging parameters included TR/TE=18 ms/6.5 ms, flip
angle = 30°, averages = 1, FOV=35 mm, matrix = 128,
resulting in a spatial resolution of 0.22× 0.22× 1 mm at a
temporal resolution of 18 ms.
Quantitative analysis of the cine MRI was performed
using a semi-automated approach employing a dedicated
software package (Munich Heart/MRIW, Technical Uni-
versity Munich, Germany) [9]. The end, epi- and endo-
cardial contours of the entire LV slices were manually
traced at end-diastolic (EDV) and end-systolic (ESV)
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lar volumes, as well as the LVEF.Cardiac PET imaging
PET was performed using the Siemens Inveon P120 PET
scanner (Siemens Healthcare Molecular Imaging, Knox-
ville, TN, USA). After placing a catheter into a tail vein,
the mice were positioned in a prone position within the
aperture of the PET scanner and were kept warm with a
heating pad so as to maintain core body temperature
within the normal range, with continuous measurement
of rectal temperature. Cardiac excitation and respiration
were measured and recorded throughout the scan using
a dedicated system (BioVet; Spin Systems Pty Ltd.,
USA). ECG electrodes were placed on both forepaws
and the left hindpaw, and respiration was measured with
a small pressure detector lying under the mouse thorax.
After intravenous administration of FDG (19 ± 5 MBq),
an ECG-gated emission recording followed throughout
the interval 60 to 90 min after tracer injection and con-
cluded with a 7-min transmission scan for attenuation
correction. Animals were returned to their home cage
for recovery. The cardiac cycle from the FDG list-mode
acquisitions was divided into eight equal intervals using
the Siemens-Inveon acquisition workplace and recon-
structed using MAP 3D with 32 iterations and OSEM
3D with 4 iterations. Since we used eight bins for gated
reconstruction, the time resolution for the PET is equal
to the mean heartbeat duration/8 for a mean heart rate
of 500 bpm resulted in a temporal resolution of 15 ms.
Each image volume consisted of 128 × 128 × 159 voxels
of size 0.4 mm×0.4 mm×0.8 mm, resulting in a volu-
metric resolution of approximately 1.5 μL [20]. Final
pixel size was magnified by a factor of ten as required
for compatibility of mouse data with QGS software tools
[21]. EDV, ESV and LVEF measurements from the PET
data sets were calculated using automated software
packages (QGS 2008 [22,23], Cedars Sinai Medical Cen-
ter, Los Angeles, USA). The automated wall recognition
proved to be robust, such that no further manual inter-
ventions were required.Infarct size
Infarct sizes were estimated from FDG-PET data as
percentage of the left ventricular myocardium area. To
this end, the entire 30 min recording was reconstructed
(MAP 3D with 32 iterations and OSEM 3D with 4
iterations in a 128 × 128 matrix) as a static image and
analysed using MunichHeartW (Technical University
Munich, Germany) with manual definition of the long
axis of the resultant polar map. The infarct area was
delineated with an intensity threshold 60% of the activ-
ity in a septal ROI [24,25].Histology
To evaluate the diagnosis of CVB3-induced DCM histo-
pathologically, the hearts were removed 12 weeks after
infection and fixed in phosphate buffered 4% formalin
prior to blocking of 2-mm thick slices, which were em-
bedded in paraffin. Five micrometre-thick sections were
cut and stained with Masson trichrome. We quantified
the extent of fibrotic lesions in picrosirius red stained
sections according to a score ranging from 0 to 4, as
previously described [26].
Statistical analyses
Data was analysed using Predictive Analysis Software 19.
Mean values and standard deviations (SD) for EDV, ESV
and LVEF were calculated. Means obtained by PET and
MRI were compared using paired Student' t test. The
agreement between the methods was visualised using
Bland-Altman plots [27]. Additionally, Pearson correl-
ation coefficients (R) and linear regressions were calcu-
lated and performed. Values of P < 0.05 were considered
statistically significant.
Results
Estimation of left ventricular functional parameters
Figure 1 shows representative end-diastolic and end-
systolic images of FDG-PET and MRI from the myocar-
dial base to the apex for animals with DCM (A), ICM
(B) and for healthy control (C) animals. There were high
correlations between LV-functional parameter (EDV,
ESV and LVEF) measurements within the entire study
group (Figure 2A,B,C). Results summarised in Table 1
show that FDG-PET significantly underestimated the
magnitudes of EDV and ESV and significantly overesti-
mated the LVEF, as compared to our reference standard
cine MRI. Bland-Altman plots confirmed the underesti-
mation of EDV and ESV, as well as the overestimation of
LVEF by FDG-PET relative to MRI, but nearly all differ-
ence values fell within ± 1.96 SD (Figure 2A,B,C right
hand side, Table 1). Considering only control mice to-
gether with the DCM group, the bias was even lower
and the limits of agreement in the Bland-Altman plots
were even more stringent (Table 1).
Correlation between infarct size and ejection fraction
There was a high negative correlation found between
the infarct sizes in the FDG images from the ICM group
and the LVEF values as measured by MRI (R= 0.98), and
a lesser correlation between the infarct sizes and the
LVEF derived from FDG-PET (R= 0.73) (Figure 3).
Monitoring LVEF in DCM mice treated with erythropoietin
Means and standard deviations for EDV, ESV, stroke vol-
ume (SV) and LVEF for the baseline and follow-up mea-
surements, along with the corresponding p values for
Figure 1 Comparison between different imaging modalities, representative images. FDG-PET versus MRI (lower row) for animals with DCM
(A, LVEF: MRI = 26%, FDG-PET = 37%), ICM (B, LV-EF: MRI = 12%, FDG-PET = 34%) and for healthy control animals (C, LVEF: MRI = 48%, FDG-
PET = 68%).
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EPO-treated group, there was a significant decrease in
the magnitude of LVEF from 55 ± 11% to 48 ± 12%
(p= 0.02), whereas the ESV significantly increased from
22 ± 8 μL to 26 ± 10 μL (p= 0.012). The EDV showed a
significant increase from 40 ± 9 μL to 52 ± 15 μL in the
saline-treated group (p= 0.031). For all other functional
parameters, no significant changes were observed in the
saline- and EPO-treated groups. There were no signifi-
cant differences in LVEF observed between EPO- and
saline-treated mice before and after treatment
(Figure 4A). Although the Student's t test revealed a sig-
nificant decrease for LVEF in the EPO-treated group, the
difference of the LVEF degradation between the saline
and the EPO groups fell just short of being significant
(p= 0.050; Figure 4B). The fibrosis scores in these mice
correlated with the LVEF measured by FDG-PET
(R= 0.86) (Figure 5).Discussion
Quantification of left ventricular functional parameters
in murine models of heart disease entails considerable
technical difficulties, arising from the small size of the
heart and its rapid movement, with heart rates typically
around 500 bpm. In the present study, we conducted a
comparison of different LV-function quantification
methods in groups of healthy mice and in two models of
cardiomyopathy. We compared FDG-PET measure-
ments acquired on a dedicated small animal PET system
with the reference standard for LV-function measure-
ments, i.e. cine MRI, which was performed with a 1.5 T
clinical scanner equipped with a microscopy coil. In the
entire study group, we found high correlations between
FDG-PET and the reference standard LV-function mea-
surements, albeit with a systematic underestimation of
the LV volumes, propagating to a net overestimation of
the LVEF by FDG-PET. Due to imperfect delineation of
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the reference standard results was markedly higher in
the ICM mice.
To our knowledge, this is the first investigation exam-
ining the fitness of ECG-gated FDG-PET for the estima-
tion of LV function in different mouse models of
cardiovascular disease within one setting. In an earlier
proof-of-principal study conducted in only two healthy
mice, Yang et al. demonstrated the technical possibility
of measuring murine LVEF with cardiac-gated FDG-PET
[11]. In another study, gated FDG-PET was validated
against echocardiography in rats with myocardial infarc-
tion [21]. Stegger et al. were the first to quantify LVFigure 2 Scatter plots of the relationship between measurements of
measurements within the entire study group by FDG-PET and by MRI for a
plot (right hand side) for all animals, for the cases of (A) EDV, (B) ESV and (volumes and ejection fraction using FDG-PET compared
to MRI [12], both in healthy mice and in mice with per-
manent (ICM) or transient LAD ligation. In contrast to
the data from human studies and to the results of [12],
we observed a significant overestimation of the LV
volumes. Furthermore, compared to their LVEF values
in healthy mice (68 ± 6% in PET and 66 ± 4% in cine
MRI), mean LVEF estimates in our mixed group of
healthy control and DCM mice (57 ± 13% in PET and
42 ± 14% in cine MRI), which were pooled so as to ob-
tain adequate statistical power for this comparison, stand
somewhat in contrast to higher corresponding results
reported by [12]. However, our decision to combine theLV parameters. Correlations between LV-functional parameter
ll animals (left hand side). alongside the corresponding Bland-Altman-
C) LVEF.
Table 1 Comparison between LV-functional parameters as calculated by cine MRI and FDG-PET for different study
subgroups
HC+DCM+ ICM HC+DCM ICM
Cine MRI FDG-PET Cine MRI FDG-PET Cine MRI FDG-PET
EDV (μL) 125 ± 80 72 ± 37* 63 ± 11 46 ± 4* 195 ± 63 103 ± 35*
Bias 52 17 92
LoA −44 to 149 −3 to 37 5 to 180
ESV (μL) 96 ± 77 42 ± 32* 38 ± 14 20 ± 6* 163 ± 63 67 ± 31*
Bias 54 18 96
LoA −47 to 155 0 to 36 3 to 190
LVEF (%) 31 ± 16 48 ± 15* 42 ± 14 57 ± 13* 18 ± 7 37± 10*
Bias −17 −15 −19
LoA −30 to −4 −26 to −5 −34 to −5
Values are presented as mean ± standard deviation for the comparison of FDG-PET with the reference method cine MRI. Furthermore the corresponding biases
and limits of agreement (LoA) calculated from Bland-Altman plots are presented. *Student's t test revealed a statistically significant difference.
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present finding of a 25% overestimation of LVEF by
FDG-PET as compared to MRI. Our finding of lower
LVEF by MRI can likely be attributed to our use of a
clinical 1.5 T MRI, whereas [12] used a 6.3 T dedicated
small animal MRI, which provides images less vulnerable
to partial volume effects, and in more slices. Further-
more, we used a semi-automated approach for the quan-
titative analysis of the cine MRI (MunichHeart/MRIW,
Technical University Munich, Germany) [9] wherein
epi- and endocardial contours of the entire left ventricle
slices were manually traced at end-diastolic and end-
systolic phases. Consequently, the definition of the heart
base is somewhat observer-dependent. Since we
acquired seven MR slices for the whole mouse heart, im-
perfect definition of the valve plane could have had an
impact on the final calculation of the corresponding left
ventricular volumes as well as on the LVEF. This limita-
tion could partially account for the bias between our
FDG-PET measurements relative to cine MR. For the
present, dedicated animal MRI systems are only availableFigure 3 Correlation between infarct size and LVEF measured by MRIat a few imaging laboratories, whereas clinical MRI
tomographs are widely available and provide a mature
and validated imaging platform for animal imaging, al-
beit with certain limitations noted above.
Similarly, our FDG-PET measurements of LVEF in
ICM mice (37 ± 10%) match the results presented by
Stegger et al. [12] (32 ± 8%) but with an even greater dis-
crepancy (nearly two-fold) between the FDG-PET and
MRI measurements. Here, another factor contributing to
our discrepant findings compared to the results of [12]
is the time-point of examination. Whereas [12] exam-
ined their mice 2 weeks after myocardial infarction, our
animals were scanned after 4 weeks, a delay which prob-
ably led to more advanced dilation of the left ventricle,
which could have hindered delineation of the endocar-
dial borders in the FDG images, propagating to a sys-
tematic overestimation of LVEF in our study. This
conjecture is supported by the fact that mean volumes
measured by MRI were much higher in our ICM group
(EDV, 195 ± 63; ESV, 163 ± 63) compared to the findings
by [12] (EDV, 122 ± 65; ESV, 94 ± 67).(A) and FDG-PET (B).
Table 2 LV–function parameters measured at baseline and after 4 weeks with FDG-PET
EPO (N=6) Baseline Follow-up P Saline (N=5) Baseline Follow-up P
EDV 47± 7 49± 9 0.371 EDV 40± 9 52± 15 0.031
ESV 22 ± 8 26± 10 0.012 ESV 20 ± 10 29 ± 16 0.078
SV 25 ± 2 23± 5 0.462 SV 20 ± 3 23± 1 0.064
EF 55 ± 11 48 ± 12 0.020 EF 51 ± 13 47 ± 11 0.345
Values are presented as mean and standard deviation, along with the corresponding p values (Student's t test).
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ies of LV function that values obtained with different
segmentation algorithms are not perfectly interchange-
able but require scaling between methods [28]. The
Cedars tools (QGSW; Cedars-Sinai Medical Center, Los
Angeles, CA) have already been used to evaluate LV
function in rodents and showed physiologically reason-
able results, as noted above. Nonetheless, the different
valve plane definitions could explain both our underesti-
mation of the LV volumes and the net effect of overesti-
mation of the LVEF by FDG-PET. Notwithstanding the
advantages imparted by cine MRI measurements, FDG-
PET, in addition to LV functional parameters, provides
reliable quantification of infarct sizes within the same
setting. Indeed, the parameter LVEF and LAD infarct
sizes are inextricably related, as demonstrated by theFigure 4 Monitoring EPO treatment with ECG-gated FDG-PET. (A) The
treatment with saline vs. EPP, and (B) the change in LVEF (Δ EF) for the salvery high negative correlations seen in the present study
(Figure 3), which exemplifies the extent to which heart
output declines with increasing area of infarcted LV.
The somewhat lower correlation between LVEF mea-
surements by FDG-PET and reference standard methods
in the ICM group should not mitigate against the use of
FDG-PET in the present DCM model. Therefore, we
chose to use FDG-PET in the EPO-treatment therapy
monitoring arm of this study. The sensitivity of func-
tional FDG-PET in this context is made clear by the
high correlation between the reduction in LVEF and the
degree of histological fibrosis (Figure 5B), which is an in-
dicator of the extent of pathological remodelling of the
myocardium. EPO is a growth factor exerting effects at
diverse targets in addition to its well-known classical ac-
tion to stimulate erythrocyte production. We havemean magnitude of LVEF before (white bars) and after (black bars)
ine and EPO groups during 1 month of treatment.
Figure 5 Correlation of LVEF as assessed by ECG-gated FDG-PET with degree of fibrosis. (A) Representative histological cardiac findings
showing myocardial fibrotic areas in CVB3-infected mice (Masson trichrome staining). (B) Correlation of degree of fibrosis obtained histology with
LVEF measured by FDG-PET.
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to intrinsic anti-apoptotic properties and also due to
mobilisation of bone marrow-derived stem cells
[13,14,29,30]. The first clinical trial of EPO in patients
with chronic heart failure gave promising findings of
increased exercise capacity and cardiac function [31,32].
However, clinical trials of EPO treatment after myocar-
dial infarction revealed discrepant results [33-35] pre-
sumably due to a trade-off between actual benefits
reflecting improved cardiac function versus correction of
incidental anaemia, further confounded by deleterious
effects arising from increased haematocrit. In previous
reports in a rodent model of myocarditis [15,16], EPO
treatment produced substantial reductions in macro-
phage infiltration and necrosis while rescuing cardiac
function when administered soon after the onset of
autoimmune pathology. However, in the present study of
mice with established CVB3-induced DCM, the EPO
treatment seemingly resulted in a significant decrease of
LVEF. Our saline-treated DCM mice showed a strong
trend towards decreasing LV function to follow-up, but
without statistical significance, such that there emerged
no notable difference between the two treatment groups.
The apparently deleterious effect of EPO treatment on
LVEF in DCM mice may be due to the high dose used in
the present study, which may have induced polycythae-
mia, resulted in impaired cardiac function. As such,
negative effects of EPO seem to have predominated over
protective effects reported in other studies.
Conclusions
In conclusion, LVEF in murine hearts measured by ECG-
triggered FDG-PET correlates highly with gated MRI mea-
surements. However, the FDG method systematicallyoverestimated LVEF relative to the gated MRI gold stand-
ard. Despite this limitation, FDG-PET served for monitor-
ing effects of EPO treatment on cardiac function in mice
with virus-induced dilatative cardiomyopathy.
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